enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. GlaxoSmithKline Carbon Neutral Laboratory - Wikipedia

    en.wikipedia.org/wiki/GlaxoSmithKline_Carbon...

    The Carbon Neutral Laboratory was designed to minimise the impact on the environment of its construction and operation. The design of the building is made up of modules manufactured off-site. The building support pillars and trusses are made from a combination of German spruce , Austrian Spruce, and American red cedar . [ 7 ]

  3. GlaxoSmithKline Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/GlaxoSmithKline...

    GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [ 4 ] [ 5 ] The company's product portfolio includes prescription medicines and vaccines .

  4. GSK plc - Wikipedia

    en.wikipedia.org/wiki/GSK_plc

    GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

  5. GSK's blood cancer drug meets primary goal in late-stage trial

    www.aol.com/news/gsk-says-blood-cancer-drug...

    Blenrep, which was the second-largest contributor to GSK's oncology business in 2022, has made about 30 million pounds ($37.38 million) in sales year-to-date. ($1 = 0.8025 pounds)

  6. GSK's asthma drug Nucala meets main goal in study on ... - AOL

    www.aol.com/news/gsks-asthma-drug-nucala-meets...

    (Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...

  7. GSK's cancer drug combination meets primary goal in late ...

    www.aol.com/news/gsks-cancer-drug-combination...

    The analysis of the full trial data, including the key secondary endpoint of overall survival, is ongoing, said GSK. ($1 = 0.7881 pounds) (Reporting by Aby Jose Koilparambil in Bengaluru; Editing ...

  8. InterAct Stroke Support - Wikipedia

    en.wikipedia.org/wiki/InterAct_Stroke_Support

    InterAct Stroke Support, previously known as the InterAct Reading Service, [1] is a charity registered with the Charity Commission Of England and Wales. [2] Its aim is to support the rehabilitation of stroke survivors through a live interactive reading service. [3]

  9. Rosiglitazone - Wikipedia

    en.wikipedia.org/wiki/Rosiglitazone

    In 2005, at the insistence of the World Health Organization, GSK performed a meta-analysis of all 37 trials involving use of rosiglitazone, finding a hazard ratio of 1.29 (0.99 to 1.89). In 2006 the GSK updated the analysis, now including 42 trials and showing a hazard ratio of 1.31 (1.01 to 1.70).